Image Sourced ShutterStock
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Roots has secured a total of $1.66 million in funding for investors
  • A$0.070 per share, representing 20 per cent discount to the 30-day VWAP of A$0.0875
  • Roots and Everblu Directors to participate in Placement with investments reaching up to A$600,000
  • RZTO to grow and pursuit of cannabis and hemp opportunities

Roots Sustainable Agricultural Technologies is an Israeli-based agricultural tech-company. Its main focus is to develop, produce and commercialise sustainable technologies which will improve plant performance.

ROO’s plan is to improve crop yield and quality, provide irrigation solutions in a cost-effective and environmentally sustainable way, for plants which othervise cant thrive in difficult weather conditions.

The funds raised will be used to commercialise its Root Zone Temperature Optimisation (RZTO) technology. RZTO influences the root temperatures of plants so they remain at an optimum root zone temperature range. This is essential for a plant’s growth, productivity and quality.

The Company will also use the funds to expand cannabis growers marketing and sales activity in the United States to fund the pursuit of new cannabis and hemp opportunities and to provide working capital.

Roots CEO, Dr Sharon Devir said,  “The placement is a strong endorsement of our substantial opportunities to commercialise our RZTO technology across multiple geographies, as we build on the momentum gained from initial sales. The funding secured in this placement will allow us to accelerate our growth in the US cannabis market, over the medium term.”

ROO by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…